Wave Life Sciences Ltd. filings document a clinical-stage biotechnology company developing RNA medicines through the PRISM platform and Nasdaq-listed $0 par value ordinary shares under WVE. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations and material-event disclosures tied to clinical programs, regulatory communications and pipeline updates for oligonucleotide candidates including WVE-006 and WVE-007.
Proxy and governance filings cover shareholder voting matters, board and governance disclosures, material agreements, capital-structure information and risk factors. The company's formal disclosures also address clinical and regulatory risks, collaboration-related matters, financial condition, and the corporate controls associated with an RNA-medicines development business.
Wave Life Sciences Ltd. furnished an updated corporate presentation for the investment community. The new presentation, dated November 17, 2025, provides business updates and is available in the Investors section of the company’s website. It is also included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain Exchange Act liabilities or automatically incorporated into other SEC filings.
Wave Life Sciences Ltd. (WVE) director Adrian Rawcliffe reported an open-market sale of company stock. On 11/13/2025, he sold 16,115 ordinary shares of Wave Life Sciences at a weighted-average price of $6.79 per share, in multiple transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2025. After this transaction, the reporting person beneficially owned 12,700 ordinary shares, held directly.
The filing notes that the shares were sold in several trades within a price range of $6.64 to $7.00 per share, and the reporting person has undertaken to provide full details of the number of shares sold at each separate price upon request by the issuer, its security holders, or the SEC staff.
Wave Life Sciences (WVE): RA Capital Healthcare Fund, L.P. and affiliated reporting persons disclosed an open-market purchase of 1,000 ordinary shares on 11/13/2025 at a weighted average price of $6.6875. Following the transaction, they reported 18,203,009 shares beneficially owned indirectly. The purchase was made to extend the period for acquisitions under the fund’s Hart-Scott-Rodino filing. Previously reported 28,815 RSUs granted to Dr. Peter Kolchinsky are held for the benefit of the fund.
Wave Life Sciences Ltd. filed a Form S-8 to register 8,000,000 additional ordinary shares reserved under the Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended. The increase of 8,000,000 shares under the plan was effective August 5, 2025.
The filing registers additional securities of the same class as previously registered on Form S-8 (File No. 333-259196) and incorporates that registration by reference pursuant to General Instruction E. It also incorporates the company’s recent 10-K, 10-Qs, proxy materials, and specified 8-Ks by reference. This is an administrative registration for an employee benefit plan rather than a public offering.
Wave Life Sciences Ltd. registered 300,000 ordinary shares on Form S-8, covering shares issuable upon exercise of options granted to a new employee under an Inducement Non-qualified Share Option Agreement dated May 27, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
This filing adds registered capacity specifically tied to that inducement option grant. It is an administrative step that facilitates the issuance of shares if and when the employee exercises the options.
Wave Life Sciences Ltd. reported Q3 2025 results. Revenue was $7.6 million, primarily from the GSK collaboration, against operating expenses of $64.0 million, resulting in a net loss of $53.9 million (basic and diluted loss per share $0.32). Other income contributed $2.5 million, mainly from interest.
Cash and cash equivalents totaled $196.2 million at September 30, 2025. Net cash used in operating activities for the first nine months was $153.7 million, partly offset by financing inflows including $42.6 million from the at-the-market equity program. Subsequent to quarter-end, the company received an additional $52.1 million in net ATM proceeds.
Deferred revenue was $58.2 million allocated to unsatisfied obligations, with $46.5 million current and $11.7 million long-term. The GSK collaboration recognized $7.6 million in Q3 revenue; a $10.0 million AATD milestone was acknowledged subsequent to quarter-end. Shareholders’ equity was $124.5 million. Ordinary shares outstanding were 167,181,784 as of November 7, 2025.
Wave Life Sciences Ltd. filed an 8-K announcing financial results for the quarter ended September 30, 2025. The accompanying press release was furnished as Exhibit 99.1 and incorporated by reference.
The company states the Item 2.02 information is being furnished and not deemed filed under the Exchange Act. Wave’s ordinary shares trade on The Nasdaq Global Market under the symbol WVE.
Wave Life Sciences filed an 8-K/A to correct a typographical error in Exhibit 99.1 of a prior 8-K and furnished the corrected press release. The company also hosted a Research Day webcast and issued a release summarizing key updates, including positive target engagement data from the ongoing INLIGHT clinical trial evaluating WVE-007 for obesity. Certain information was furnished under Item 7.01 and incorporated by reference under Item 8.01.
Wave Life Sciences (WVE) filed an 8-K announcing a Research Day webcast held on October 29, 2025, and made the slide presentation available on its investor website. The company also furnished a press release summarizing highlights from the event, including positive target engagement data from the ongoing INLIGHT clinical trial evaluating WVE-007 for obesity.
The materials are provided under Regulation FD as Item 7.01 information furnished, not filed, and thus are not subject to Section 18 liabilities. The press release (other than its second paragraph) is incorporated by reference into Item 8.01. Exhibit 99.1 contains the press release; the cover page interactive data file is included as Exhibit 104.
Wave Life Sciences Ltd. furnished an updated corporate presentation to the investment community. The presentation, dated September 24, 2025, provides updates and summaries of the company’s business and is available in the “For Investors & Media” section of its website and as Exhibit 99.1. The information is furnished under a regulation fair disclosure item and is not considered filed for liability purposes under the Exchange Act, unless specifically incorporated into another filing.